Developing Stem Cell Therapies for Parkinson's Disease

This open access review covers attempts by the research community to produce a cell therapy to treat Parkinson's disease, a condition driven by the accelerated loss of a small but vital population of brain cells. This loss happens to everyone over the course of aging to a much lesser degree, and thus progress towards treatments is of general interest. In theory these lost cells could be replaced, but in practice getting to the point of a reliable treatment along those lines is entwined with the ongoing development of stem cell medicine as a whole. Robust methods of cell production, transplant, and engineering, along with sufficiently comprehensive knowledge of cell biology to steer this work are all still in progress, further along for some types of cell and tissue, less well advanced for others:

Parkinson's disease (PD) is one of the most common neurodegenerative disorders of aging, affecting about 1% of the population aged 60 years and older and 3-5% of the population above the age of 85. The various disruptions in motor control typically appear when 60-80% of dopamine (DA) neurons in the substantia nigra are degenerated. Because DA neurons degenerate to cause a drop in dopamine release, current treatments for PD include dopamine replacement drugs and deep brain stimulation (DBS) to the nucleus subthalamicus. Even though dopamine replacement drugs and DBS are effective in improving the symptoms of the patients, they cannot stop the disease progression. Moreover, current medications can cause the development of involuntary muscle movements, effectively "overshooting" the clinical symptoms of PD.

Recent research progress has provided treatment potential through replacing lost DA neurons using neural stem cells (NSCs) or fully differentiated DA neurons from fetal brain tissue, embryonic stem cells (ESCs), mesenchymal stem cells (MSCs) sourced from adults or fetuses, and induced pluripotent stem cells (iPSCs) reprogrammed from patients' somatic fibroblasts or blood cells. Much work has been done to adapt cells from various sources to potential clinical applications to improve treatments for neurodegenerative diseases including PD. NSCs and DA neurons from fetal brain and hESCs are not suitable for clinical use because of their immune-rejections and ethical issues. The availability of iPSCs and iDA neurons paved the road for autologous cell-based therapy of PD. However, several aspects of iPSCs need to be resolved before they go to clinical use. These include low yields of DA neurons, genetic and epigenetic abnormalities, and the safety of iPSC-derived cells.

Cell replacement therapy is a promising avenue for the treatment of PD and other neurodegenerative disorders. The use of all cell sources derived is fraught with ethical, logistical, and safety concerns. However, scientific research is making great progress in the development and characterization of iPSC derived cells for PD. iPSCs and their derivatives injected into animal models have shown promise in treatment of disorders such as PD; however, iPSCs have not been used in clinical trials for PD. There are some limitations/disadvantages associated with iPSCs. A relevant therapeutic progenitor or mature cell type may be identified and grafted in such treatments; in the case of PD, the options are, of course, iPSC-derived NSCs and iPSC-derived DA neurons. Theoretically, these two should act just like their non-iPSC derived counterparts - in actuality, because of the concerns mentioned above, the unique iPSC heritage of such cells sometimes poses its own unique set of problems.

Pre-clinical studies on viability might also be necessary to establish the scope of the treatment. iPSCs would not be moved to clinical trials at least until iPSCs are better understood and efficient and safe methods for reprogramming and gene correction are developed. The pace of progress will no doubt continue to speed along in the years to come, and it is therefore quite likely that within our lifetime we will witness the jump from dish to clinic.



And here's where the real work is.

Once humanity masters iPSCs (and, of course, the accompanying signaling environment), we can regenerate literally anything on or in the human body. Teeth? Grow new ones. Brain cells? Here you go. Arms. Legs. Whole organs. Or parts thereof.

The problems, which this article points out, are the genetics/epigenetics and other physical problems with the cells. I suspect that if iPSCs are to truly work for all applications, they need to be totally indistinguishable from fetal cells on every level, including things like telomere length. The "heritage" talked about here needs to be gotten rid of.

"safe methods for reprogramming and gene correction are developed"

Ding ding ding. There's the $64,000,000,000 question.

Posted by: Slicer at September 10th, 2015 10:48 AM

Blasco just released a method that greatly improves stem cells and their genomic stability.

Posted by: Steve h at September 10th, 2015 2:54 PM

Then Blasco may have just saved millions of lives. Link?

Posted by: Slicer at September 10th, 2015 3:00 PM

Sorry it's cnio where blasco is based, they do excellent work.they found a way to improve stem cells and reduce the damage when reprogramming them.I am unsure how important this is but it seems to be.

Posted by: Steve h at September 10th, 2015 3:13 PM

It's still not a guarantee of error-free stem cells (or fewer errors than the adult line), but it's a major step forward.

Posted by: Slicer at September 10th, 2015 3:20 PM

Yeah I thought it was good. They will be trying to improve on that for sure.

Posted by: Steve h at September 10th, 2015 3:55 PM

Real stem cell therapy is to induce 'adult stem cells' inside of body differentiating into specified cells for repairment of damaged tissue and organ. Adult stem cells should be IN SITU for differentiation. Alas, global research of stem cell therpay is completely.

Nano-medication is based on:

God formed man out of dirt from the ground and blew into his nostrils the breath of life.

Nano-medication should be the last-ditch treatment for PD (Parkinson's Disease), dementia and/or other brain diseases. Cirrhosis, osteonecrosis, degenerative osteoarthritis, etc. all can be treated so well by nano-medication without any side effects.

God prepare more than enough adult stem cells inside of human body for repairment of damaged tissue and organ. It sounds very strange that global research of stem cell therapy never considers how to induce 'adult stem cells' for differentiation in SITU.

Posted by: David Lo at December 17th, 2015 11:07 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.